Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Scientists identify new way to block action of genetic mutations found in most cancers

Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers.

7 Nov 2016

Using deep learning to update the drug discovery paradigm: an interview with Professor Jackie Hunter

With the current drug discovery paradigm, it takes up to 15 years to translate an idea, such as hypothesizing a certain protein is important in a disease and testing this with targeting the protein with a drug, all the way through to proof of concept...

2 Nov 2016

Researchers develop new way to prevent diseases caused by herpesvirus infections

A new approach has been developed to combat diseases caused by herpesvirus infections, including everything from cold sores to cancer.

1 Nov 2016

Supercomputer simulations of p53 protein could boost future anti-cancer drug discovery

Even though it's almost impossible to see, computational biophysicist Rommie Amaro is using the Stampede supercomputer at the Texas Advanced Computing Center at The University of Texas at Austin to model the largest atomic level system of the tumor suppression protein p53 to date -- over 1.5 million atoms.

27 Oct 2016

New drug appears to decrease inflammation in the brain linked to Alzheimer's disease

An experimental drug shows promise in treating Alzheimer's disease by preventing inflammation and removing abnormal protein clumps in the brain that are associated with the disease, suggests a study in mice presented at the ANESTHESIOLOGY 2016 annual meeting.

25 Oct 2016

Novel C. elegans worm strain could serve as tool for testing interventions against AD

Researchers from Yale-NUS College have partnered with researchers from the National University of Singapore and SingHealth Group to develop a novel Caenorhabditis elegans (C. elegans) worm strain which expresses an amyloid beta protein fragment involved in the development of human Alzheimer's Disease (AD).

25 Oct 2016

MTPConnect to provide $7.4 million funding for 14 national projects in medtech, biotech and pharmaceutical sector

MTPConnect - the Medical Technologies and Pharmaceuticals Industry Growth Centre - today announced it will provide $7.4 million of funding over two years for 14 national projects in the medtech, biotech and pharmaceutical (MTP) sector.

25 Oct 2016

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered a mechanism that confers resistance to drugs used to treat certain types of acute myeloid leukemia (AML).

24 Oct 2016

Two leading non-profit organizations sign strategic affiliation to hasten drug development

The Scripps Research Institute and the California Institute for Biomedical Research - two leading non-profit research organizations - today announced the signing of a strategic affiliation that combines the two organizations into a new biomedical research entity with the tools and know-how to rapidly translate its scientific discoveries into life-saving medicines for the public benefit.

20 Oct 2016

Scientists modify structure of cancer drug to enhance ability to pass through blood-brain barrier

In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.

20 Oct 2016

New stem cell-based strategy may help predict heart-damaging effects of drugs

Coaxing stem cells from patients to become heart cells may help clinicians personalize drug treatments and prevent heart-related toxicity.

17 Oct 2016

Activation of chemical with ER-β may help reduce obesity by converting white fat to brown fat

New research, published online in The FASEB Journal, suggests that activation of a chemical called Beta-LGND2 by the estrogen receptor Beta (ER-Beta) reduces obesity and metabolic diseases in mice by converting bad fat (white fat) to good fat (brown fat).

17 Oct 2016

U of A researchers to study origin of Leigh's disease

Researchers at the University of Arkansas and their collaborators will use a $1.4 million grant from the U.S. Department of Defense to study the origin of Leigh's disease, a rare and incurable disease that affects the central nervous system.

13 Oct 2016

Virginia Tech scientists solve structure of enzyme that deactivates important antibiotic

A popular antibiotic called rifampicin, used to treat tuberculosis, leprosy, and Legionnaire's disease, is becoming less effective as the bacteria that cause the diseases develop more resistance.

7 Oct 2016

New study of Phase II Alzheimer's drug pipeline reveals more ways to combat disease

A new analysis of the Phase II Alzheimer's drug pipeline, conducted by ResearchersAgainstAlzheimer's, revealed 57 new Alzheimer's drugs. According to the analysis, nearly twice as many mechanisms of action are being tested in Phase II than in Phase III clinical trials.

7 Oct 2016

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

Women may have better verbal memory skills than men even when their brains show the same level of problems metabolizing glucose, which occurs in people with Alzheimer's disease, according to research published in the October 5, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.

5 Oct 2016

Novel bifunctional dimers show promise in preventing Parkinson's disease

A team of researchers from the University of Saskatchewan has developed two caffeine-based chemical compounds that show promise in preventing the ravages of Parkinson's disease.

30 Sep 2016

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to lead its integrated genomics initiative, which was announced in April.

30 Sep 2016

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.

30 Sep 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Drug Discovery News and Research

Further Reading

Scientists identify new way to block action of genetic mutations found in most cancers

Using deep learning to update the drug discovery paradigm: an interview with Professor Jackie Hunter

Researchers develop new way to prevent diseases caused by herpesvirus infections

Supercomputer simulations of p53 protein could boost future anti-cancer drug discovery

New drug appears to decrease inflammation in the brain linked to Alzheimer's disease

Novel C. elegans worm strain could serve as tool for testing interventions against AD

MTPConnect to provide $7.4 million funding for 14 national projects in medtech, biotech and pharmaceutical sector

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Two leading non-profit organizations sign strategic affiliation to hasten drug development

Scientists modify structure of cancer drug to enhance ability to pass through blood-brain barrier

New stem cell-based strategy may help predict heart-damaging effects of drugs

Activation of chemical with ER-β may help reduce obesity by converting white fat to brown fat

U of A researchers to study origin of Leigh's disease

Virginia Tech scientists solve structure of enzyme that deactivates important antibiotic

New study of Phase II Alzheimer's drug pipeline reveals more ways to combat disease

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

Novel bifunctional dimers show promise in preventing Parkinson's disease

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

Assay Development and Screening Models eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo